Skip to main content
. Author manuscript; available in PMC: 2024 Sep 13.
Published in final edited form as: Front Trop Dis. 2021 Aug 26;2:719369. doi: 10.3389/fitd.2021.719369

FIGURE 1 |.

FIGURE 1 |

Antigen characteristics of advanced schistosomiasis vaccine candidates which progressed to pre-clinical and clinical development (details in Supplementary Tables S1–S4). Sm, Schistosoma mansoni; Sh, Schistosoma haematobium; TSP, tetraspanin; GST, glutathione S-transferase; cGMP, current Good Manufacturing Practice; AP10–701, glucopyranosyl lipid A (aqueous formulation); GLA-SE, glucopyranosyl lipid A in stable emulsion (TLR4 agonist); CpG-ODN, oligodeoxynucleotides with unmethylated CpG dinucleotides (TLR9 agonist).